Arcus Biosciences, Inc. (32)

Browse by Contract Category

Contracts

Letter Agreement with Gilead Sciences, Inc. dated July 1, 2022 (Filed With SEC on August 3, 2022)
Non-Employee Director Compensation Program (Filed With SEC on June 16, 2022)
Amendment No. 1 dated November 17, 2021 to the Option, License and Collaboration Agreement dated May 27, 2020 between Arcus Biosciences, Inc. and Gilead Sciences, Inc (Filed With SEC on February 23, 2022)
Third Amendment dated May 10, 2021 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics Ireland Limited (Filed With SEC on August 5, 2021)
Fifth Amendment Dated April 1, 2021 to the Lease agreement dated September 30, 2015 between Arcus Biosciences, Inc. and Hayward Point Eden I Limited Partnership (Filed With SEC on May 5, 2021)
Description of Common Stock (Filed With SEC on February 25, 2021)
Arcus Biosciences, Inc. Amended and Restated 2020 Inducement Plan (Filed With SEC on February 23, 2022)
Separation and Consulting Agreement by and between the Company and William Grossman dated July 16, 2021 (Filed With SEC on August 5, 2021)
Non-Employee Director Compensation Program (Filed With SEC on June 7, 2021)
Arcus Biosciences, Inc. 2018 Equity Incentive Plan Notice of Restricted Stock Unit Award (Filed With SEC on February 25, 2021)
Arcus Biosciences, Inc. 2018 Equity Incentive Plan Notice of Stock Option Grant (Filed With SEC on February 25, 2021)
Dated November 10, 2020 Arcus Biosciences, Inc. WuXi Biologics (Cayman) Inc. and WuXi Biologics Ireland Limited (Filed With SEC on February 25, 2021)
Arcus Biosciences, Inc. Amended and Restated 2020 Inducement Plan (Filed With SEC on February 25, 2021)
Offer letter by and between Arcus Biosciences, Inc. and Jennifer Jarrett dated September 10, 2020 (Filed With SEC on November 5, 2020)
Fourth Amendment dated October 16, 2020 to the Lease agreement dated September 30, 2015 between Arcus Biosciences, Inc. and Hayward Point Eden I Limited Partnership (Filed With SEC on November 5, 2020)
Offer letter by and between Arcus Biosciences, Inc. and Robert C. Goeltz II dated June 30, 2020 (Filed With SEC on November 5, 2020)
Non-Employee Director Compensation Program (Filed With SEC on June 5, 2020)
Underwriting Agreement, dated as of May 28, 2020, by and among Arcus Biosciences, Inc., Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group L.L.C (Filed With SEC on May 29, 2020)
Amendment No. 2 dated March 2, 2020 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc (Filed With SEC on March 5, 2020)
Arcus Biosciences, Inc. Restricted Stock Unit Grant Notice (2020 Inducement Plan) (Filed With SEC on March 5, 2020)
Arcus Biosciences, Inc. Stock Option Grant Notice (2020 Inducement Plan) (Filed With SEC on March 5, 2020)
Arcus Biosciences, Inc. 2020 Inducement Plan (Filed With SEC on March 5, 2020)
Amendment to Separation and Consulting Agreement by and between the Company and Jennifer Jarrett dated January 3, 2019 (Filed With SEC on March 5, 2020)
Compensation Program for Non-Employee Directors (Filed With SEC on March 5, 2020)
Description of Common Stock (Filed With SEC on March 5, 2020)
Separation Agreement, dated August 29, 2019, between the Company and Rekha Hemrajani (Filed With SEC on November 5, 2019)
Offer Letter, dated May 20, 2019, between the Company and Jason Barker (Filed With SEC on November 5, 2019)
Amendment No. 1 dated June 27, 2019 to the License Agreement dated August 16, 2017 between Arcus Biosciences, Inc. and WuXi Biologics (Cayman) Inc (Filed With SEC on August 6, 2019)
Offer Letter, dated March 16, 2019, between the Company and William Grossman (Filed With SEC on August 6, 2019)
Offer Letter, dated February 22, 2019, between the Company and Rekha Hemrajani (Filed With SEC on May 2, 2019)
Separation and Consulting Agreement by and between the Company and Steven Chan dated March 1, 2019 (Filed With SEC on March 5, 2019)
Separation and Consulting Agreement by and between the Company and Jennifer Jarrett dated January 3, 2019 (Filed With SEC on March 5, 2019)